TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Electrical Stimulation to Promote Recovery in Bells Palsy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* New diagnosis of bell's palsy (diagnosed in the last 30 days)~* IF younger than 60 years of age must have complete paralysis on one side of face or both~* IF older than 60 years of age paralysis must be present but CAN be incomplete.~Exclusion Criteria:~* Paralysis associated with any of the fallowing: cancer, tumor, surgery, stroke, or trauma.~* Younger than 60 years old with INCOMPLETE paralysis.~* Non English speakers~* Pacemaker or deep brain stimulator

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- High-volt electrical stimulation (Type: EXPERIMENTAL): Plan to use a monophasic waveform having 100µmsec pulse duration, at 35 Hz using tolerated voltage to generate a contraction a total of 20 minutes.~The stimulation will have 10 seconds on time, 30 seconds off time and 2 second ramp up and down. Electrical stimulation will be produced with the Orthostim 3 device (VQ Ortho Care). The cathode will be placed on the ipsilateral muscle to stimulate and the anode over the ipsilateral mastoid region.~Four facial muscles will be stimulated: 1)frontalis, 2) orbicularis oculi, 3) zygomaticus major, and 4) orbicularis oris.~The voltage is turned up by the participant until he or she can see twitches or as high as tolerated. Ten contractions in each muscle group will be performed or 5 minutes per muscle if no contraction is achieved.
- Subsensory electrical stimulation (Type: PLACEBO_COMPARATOR): Plan to use the same device and settings to provide placebo treatment by delivering minimal electricity. The settings will be the same as the intervention except the voltage will be subsensory. ie. below the minimum at which patients feels any effect of the current.~The voltage is turned down two clicks from the voltage at which the participant can first notice any electricity or at the minimal setting.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Assessment of Flow With the New Four-dimensional Velocity-encoded Magnetic Resonance Imaging Technique

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* All pediatric patients under 18 years of age undergoing CMR with 2D PC flow measurements as a clinically indicated component of the examination at The Hospital for Sick Children, Toronto, ON.~* Ability to undergo an MRI examination without anesthesia or sedation.~* Ability to undergo an MRI examination using 'Feed-and-Sleep' technique39~Exclusion Criteria:~* Refusal of consent / assent by parent / legal guardian / patient~* General contraindications for an MRI examination such as non-MRI compatible metallic implants, claustrophobia.~* Patients who require anaesthesia or sedation for MRI

- Gender: ALL
- Minimum Age: 1 Day
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Study Participants (Type: EXPERIMENTAL): 4D PC MRI acquisition

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Haematopoietic Stem Cell Transplantation (HSCT) in Comparison to Conventional Consolidation Therapy for Patients With Acute Myeloid Leukemia (AML) (Intermediate Risk) </= 60y. After First CR

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* AML in first remission~* cytological standard risk, i.e. karyotype not listed under exclusion criteria~* Identification of HLA-identical sibling or HLA-compatible related or unrelated donor (9/10 HLA-alleles matched, high resolution typing for HLA-A, B, Cw, DRB1 and DQB1)~* age: 18 - 60 years~* medically fit for allogeneic stem cell transplantation~* CR / CRi after induction therapy~Exclusion Criteria:~* core-binding factor leukemia (t(8;21), inv16)~* acute promyelocytic leukemia (t(15;17)~* complex aberrant karyotype~* karyotypes: -7; -5; del5q; t(3;3); t(6;11), t(6;9), 11q aberrations, trisomy 8 ± one single additional aberration~* pregnancy / nursing~* non-compliance

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Human Stem Cell Transplantation (Type: EXPERIMENTAL): Patients receive an allogenic stem cell transplantation from an HLA-matched unrelated or related donor
- Consolidating Chemotherapy (Type: ACTIVE_COMPARATOR): Patients receive a standard chemotherapy as consolidation therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: A Phase III Study to Investigate the Impact of Diamyd in Patients Newly Diagnosed With Type 1 Diabetes (USA)- DIAPREVENT

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Main Inclusion Criteria:~* Insulin dependent type 1 diabetes mellitus diagnosed within the previous 3 months at time of screening~* Fasting C-peptide level at time of screening above 0.1 nmol/L~* Elevated GAD65 antibodies (GADA) at time of screening~* Male and female patients between 10 and 20 years of age~Main Exclusion Criteria:~* Treatment with immunosuppressants or any anti-diabetic medications other than insulin~* A history of certain diseases or conditions (e.g. anemia, HIV, hepatitis, epilepsy, head trauma, neurological diseases or cerebrovascular accident, alcohol or drug abuse etc)~* Treatment with any vaccine within 1 month prior to planned first Diamyd dose or planned treatment with vaccine up to 2 months after the last injection with Diamyd, excluding the influenza vaccine~* Participation in other clinical trials with a new chemical entity within the previous 3 months~* Pregnancy or planned pregnancy within 1 year after the last Diamyd dose~* Presence of associated serious disease or condition which in the opinion of the investigator makes the patient non-eligible for the study

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: 20 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: ACTIVE_COMPARATOR): This arm will receive 2 subcutaneous injections with 20 µg Diamyd on days 1 and 30, i.e., 1 prime and 1 booster dose, followed by 2 additional single doses with Diamyd 20 µg on days 90 and 270.
- B (Type: ACTIVE_COMPARATOR): This arm will receive 2 subcutaneous injections with 20 µg Diamyd on days 1 and 30, i.e., 1 prime and 1 booster dose, followed by 2 additional single doses with placebo on days 90 and 270.
- C (Type: PLACEBO_COMPARATOR): This arm will receive 4 injections of placebo, 1 each on days 1, 30, 90 and 270.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Bosentan Use in Patients With Diabetic Nephropathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men or women ≥ 18 years of age with a body weight of ≥ 40 kg;~* For female patients, only non-pregnant women who are surgically sterile, postmenopausal or have documented infertility (over 50 years of age and amenorrheic for at least 1 year), or those of childbearing potential using intrauterine devices (IUDs);~* Patients diagnosed Type 2 diabetes with overt nephropathy (urinary albumin excretion ≥ 300mg/24h);~* Patients on current treatment with angiotensin II receptor blockers for ≥ 3 months;~* Patients stable for at least 3 months prior to screening (no change in medications for diabetic nephropathy);~* Provide written informed consent;~Exclusion Criteria:~* Patients with a history of pulmonary chronic obstructive disease, cardiac failure or coronary artery disease;~* Patients with documented cancers, acute infections or chronic inflammatory diseases;~* Patients who are pregnant or breast-feeding;~* Patients with known hepatic disorders or AST and ∕or ALT upper than normal limit;~* Patients with hemoglobin or hematocrit that is ≥ 30% below the normal range (patients with secondary polycythemia are permitted);~* Patients with systolic blood pressure \< 110mm Hg;~* Patients with plasmatic albumin level \< 30g/L;~* Patients with a documented creatinine clearance ≤ 60ml/min;~* Patients on anticoagulants or anti-inflammatory drugs, including cyclooxygenase inhibitors, AINS, prednisone and immunosuppressive drugs, platelet aggregation inhibitors, except low dose aspirin, ACE inhibitors, antidiabetic agents (rosiglitazone, pioglitazone) and antioxidants (vitamin E)(except statins or low-dose aspirin ≤ 80mg/day);~* Patients on treatment or planned treatment with another investigational drug;~* Patients who are receiving an endothelin receptor antagonist, phosphodiesterase type 5 inhibitor, or with a prostanoid (excluding acute administration during a catheterization procedure to test vascular reactivity) within 2 months of inclusion;~* Patients who are receiving calcineurin-inhibitors (i.e., cyclosporine A and tacrolimus), fluconazole, glibenclamide (glyburide) at inclusion or are expected to receive any of these drugs during the study;~* Patients with a known hypersensitivity to bosentan or any of the excipients;

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Bosentan 62.5mg bid x4 weeks; up-titrated to 125mg bid x12 weeks;
- 2 (Type: PLACEBO_COMPARATOR): placebo given bid same as experimental arm;

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of a Learning Program of Self- Rehabilitation Exercises by Mirror Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Affiliation to Social Security~* CRPS (complex regional pain syndrome) type I or II defined by the criteria of Bruehl (Table 1)~* CRPS of the upper limb including the wrist and / or hand~* CRPS post-surgical or post-traumatic~* Average pain in the last 24 hours of intensity \> = 30/100 on EVA (0 no pain, 100: worst pain imaginable )~* Evolution for over 3 months and less than 2 years~* Patients taking a stable background therapy for 15 days and not having received the following treatments in the previous months : bisphosphonate cure, infiltration, Qutenza, ketamine infusions~* Patients accepting a rehabilitation (physiotherapists or hospital units for patients included on Saint-Etienne and hospital units for patients included in Lyon and Saint- Vallier)~Exclusion Criteria:~* CRPS post stroke or drug~* Adhesive capsulitis isolated~* Cognitive or language difficulties preventing understanding instructions and / or a correct clinical evaluation~* Patient who already received a rehabilitation program with the use of mirror therapy or other virtual reality technology~* CRPS in connection with an accident caused by a third party for which a legal procedure is underway~* Major Depressive Episode~* Dissociative Disorders~* Visually impaired patients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Experimental group : Mirror Therapy (Type: EXPERIMENTAL): Experimental group will perform mirror therapies during 16 weeks, added to the usual care. Therapy mirror sessions will take place at hospital units but also at home.
- Control group : Usual care (Type: ACTIVE_COMPARATOR): The control group will benefit from the usual care during 16 weeks. No mirror therapies will be performed to this group.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Transcutaneous Raman Spectroscope (TRS) Analyses of Diabetic Foot Ulcers

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DEVICE_FEASIBILITY
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Ability to provide informed consent~* Diagnosis of diabetes mellitus~* Full thickness or superficial foot and ankle ulcers based on clinical assessment (e.g., University of Texas (UT) grades 1-3, stages A-D). For reference, see Appendix 1 for the UT classification table~Exclusion Criteria:~* Age less than 18 or greater than 80 years old~* Subject has a psychological or sociological condition or an addictive disorder that would preclude informed consent~* Completely epithelialized ulcer based on clinical assessment with no ischemia or infection (UT classification 0A)~* Current or previous use of anti-resorptive bisphosphonate drugs (e.g., risedronate (Actonel) and alendronate (Fosamax))

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- TRS (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Botulinum Toxin Type A (Botox) in the Management of Levodopa-Induced Peak-Dose Dyskinesias in Parkinson's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients must have idiopathic PD (by standard clinical criteria).~2. Patients must have persistence of LID despite optimization of anti-Parkinsonian medication (duration of LID \> 1 \[duration of at least 1-25% of the waking time\] on item 32 of the United Parkinson's Disease Rating Scale \[UPDRS\]).~3. Patients must have severity of LID \> 1 \[mildly disabling\] on item 33 of the UPDRS.~4. Patients must have a Mini-Mental State score of \> 24.~5. Patients must be willing and able to give consent.~Exclusion Criteria:~1. Patients who are older than 75 years of age.~2. Patients who have a Parkinsonian syndrome that is unresponsive or weakly responsive to levodopa (improvement \< 30%).~3. Patients who require concurrent use of warfarin or other anticoagulating agents.~4. Uncontrolled clinically significant medical condition other than the condition under evaluation~5. Known allergy or sensitivity to any of the components in the study medication.~6. Concurrent participation in another investigational drug or device study or participation in the 30 days immediately prior to study enrollment.~7. Any medical condition that may put the subject at an increased risk with exposure to Botox including diagnosed myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis, or any other disorder that might interfere with neuromuscular function.~8. Evidence of recent alcohol or drug abuse.~9. Infection or skin disorder at an anticipated injection site (if applicable).~10. Any condition or situation that, in the investigator's opinion, may put the subject at significant risk, confound the study results, or interfere significantly with the subject's participation in the study.

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Botox (Type: EXPERIMENTAL): Randomized into receiving Botox first. At cross-over, patients will receive placebo.
- Placebo (Type: PLACEBO_COMPARATOR): Randomized to receive placebo first. At cross-over, patients will receive the active Botox.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: A Prospective Randomized Controlled Trial on the Use of Bone Morphogenetic 7 (BMP-7) (OP-1®) and Demineralized Bone Matrix in Tibial Non-union

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diaphysary tibial non-unions will be included (9 months after first surgery)~* Major surgery includes exchange nailing, bone grafting, internal fixation, amputation and soft-tissue coverage procedures, such as delayed primary closure and free flaps~* Surgery is classified as minor for removal of external fixator pins for local infection and removal of a static locking screw from intramedullary nails, a procedure known as dynamization~* ASA 1 and ASA 2~* Gap length/bone contact detected (1-5 cm): largest cortical gap in any radiographic incidence~* Subject or legal guardian is willing and able to understand, sign and date the study specific Patient Informed Consent, which has been approved by the Institutional Review Board~* Agrees to participate in post-operative evaluations and required rehabilitation regimen~Exclusion Criteria:~* Patients with known hypersensitivity to the active substance or collagen~* Gap more than 5 cm~* Immature skeleton~* Known auto-immune disease, including rheumatoid arthritis, systemic lupus erythematosus, scleroderma, Sjögren's syndrome and dermatomyositis/polymyositis~* Active infection on unhealed site or active systemic infection~* Non-healing resulting from pathological fractures, tumours or metabolic bone diseases~* Presence of tumour in vicinity of non-union~* Patients receiving chemotherapy, radiotherapy or immunosuppressant treatment or excessive steroids~* Patients with severely compromised soft tissue coverage or vascularisation at the non-union site, sufficient to impair bone healing~* Patients with congenital non-union~* Pregnancy and lactation~* Non-union of multiple bones interfering with walking~* Patients with neuromuscular diseases or conditions interfering normal weight bearing~* Patients who, judged by the surgeon, are candidates for just internal fixation alone

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 2 (Type: ACTIVE_COMPARATOR): non-union of diaphysary tibial fractures will be treated with allograft together with DBM
- 1 (Type: EXPERIMENTAL): non-union of diaphysary tibial fractures will be treated with BMP-7 in adjunct to fresh frozen allograft

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Paclitaxel Detection in NSCLC Treated With TC Regimen

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age: 18 \~75 years~* Pathology: Confirmed by pathology (histology or cytology) for advanced non-small cell lung cancer~* Have indications of paclitaxel/carboplatin chemotherapy, suitable for paclitaxel chemotherapy (independent of clinical tumor stage or chemotherapy type or palliative chemotherapy lines)~* At least one measurable tumor lesions (according to RECIST 1.1 criteria)~* ECOG PS score: 0 to 2 points~* Life expectancy: more than 3 months~* Bone marrow reserve function is good, the function of organs (liver and kidney) is good, can satisfy the conditions of implementation chemotherapy. neutrophil count ≥1.5×109/l, platelet ≥75×109/l, hemoglobin \>9g/dl, Total Bilirubin ≤1.5×ULN\*, transaminase \<2.5×ULN\*, creatinine ≤1.5×ULN\*,or creatinine clearance rate ≥45ml/min. ULR: Upper Limit Of Normal.~* Sign the informed consent form; Compliance is good, can be followed up, willing to comply with the requirements of the study~Exclusion Criteria:~* ECOG Performance Scores \> 2 points~* Organic disease (heart, liver, kidney disease etc), Active infection Organ transplantation immunosuppressive therapy, not capable to complete 4 - 6 cycles of paclitaxel / carboplatin chemotherapy.~* Any other tumor history not cured in 3 years before this trial.~* Bone marrow function or organs function not eligible for chemotherapy.~* Diabetic patients currently receiving the standard anti- diabetes treatment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Paclitaxel and Carboplatin regimen (Type: EXPERIMENTAL): Paclitaxel: 175mg/m2, d1; Intravenous drip injection with 500ml N.S Carboplatin: AUC=5, d1; Intravenous drip injection with 500ml G.S Paclitaxel injection at first, followed with Carboplatin injection. 21 days per cycle; 6 cycles in total.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Allogeneic Stem Cell Transplantation in Pediatric Patients With Malignant and Non-malignant High-risk Diseases

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients aged 0 to 30 years~* Written informed consent from patient and/or parents or guardian~* Patients with Karnofsky Index \> 60%~* Malignant disease:~  * acute lymphoblastic leukemia~ * acute myeloid leukemia~ * myelodysplastic syndrome~ * chronic myeloid leukemia according to the standard indications~ * solid tumors (e.g. neuroblastoma recurrence, soft-tissue sarcoma, Ewing's sarcoma, osteosarcoma, hepatoblastoma)~    . Non malignant disease:~ * acquired anemias (e.g. severe aplastic anemia, particularly severe Evans syndrome)~ * congenital anemias (e.g. thalassemia and sickle cell anemia)~* Women reliable contraception method when appropriate~Exclusion Criteria:~* Participation in other clinical trials~* Patients, parents, or guardians unable to understand the nature, the importance and the implications of the procedure~* Pregnant or nursing women~* Patients who underwent a stem cell transplantation in the last 250 days~* Patients with kidney, heart or liver insufficiency

- Gender: ALL
- Minimum Age: None
- Maximum Age: 30 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues